Latest Conference Articles

MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.

Pembrolizumab Nears 50% Response in High PD-L1-Expressing NSCLC

April 19th 2015, 4:40pm

Pembrolizumab had an overall response rate (ORR) of 45.2% among a cohort of patients with PD-L1-positive nonâ€“small cell lung cancer (NSCLC) and an ORR of nearly 20% in the full population in the phase I KEYNOTE-001 trial.

Breakthrough T-Cell Therapy Halts EBV-Associated Lymphoproliferative Disorders

April 19th 2015, 4:35pm

Infusions of Epstein-Barr virus (EBV)â€“specific cytotoxic T lymphocytes from healthy donors led to high response rates and significant extensions in overall survival for patients with rituximab-refractory EBVâ€“associated lymphoproliferative disorders.

Frontline Pembrolizumab Trumps Ipilimumab in Head-to-Head Melanoma Trial

April 19th 2015, 4:30pm

Pembrolizumab elicited significantly better outcomes compared with ipilimumab in a randomized phase III trial of patients with advanced melanoma.

Dr. Heymach on New KRAS Subsets in Lung Cancer

April 19th 2015, 11:57am

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.

Bispecific Immunotherapy Elicits Intriguing Responses in Melanoma

April 19th 2015, 8:45am

IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.

Fosbretabulin/Bevacizumab Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer

March 31st 2015, 10:12am

Fosbretabulin plus bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in patients with recurrent ovarian cancer.

Bevacizumab Regimen Shows Survival Trend in Phase III Ovarian Cancer Trial

March 30th 2015, 4:15pm

Treatment with bevacizumab plus a chemotherapy doublet extended overall survival by nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer

March 30th 2015, 4:09pm

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage III/IV ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not in an open-label phase II trial.

Studies Illuminate Olaparib's Continued Role in Ovarian Cancer

March 30th 2015, 6:00am

Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib in the treatment of women with ovarian cancer, according to Ursula A. Matulonis, MD.

Studies of Second-Line Immunotherapies in Bladder Cancer Hold Promise

March 16th 2015, 1:28pm

With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.

Gomella Discusses Optimizing Sipuleucel-T in mCRPC

March 16th 2015, 1:07pm

In an interview with OncLive, Leonard G. Gomella discusses the benefits, limitations, and considerations of sipuleucel-T for patients with prostate cancer.

Dr. Benson on Challenges of Active Surveillance for Prostate Cancer

March 16th 2015, 12:45pm

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses potential issues with active surveillance for patients with intermediate-risk prostate cancer.

Dr. Dreicer on Sequencing Therapies for Patients with Prostate Cancer

March 16th 2015, 12:04pm

Robert Dreicer, MD, MS, FACP, FASCO, Division of Hematology and Oncology, Department of Medicine, University of Virginia School of Medicine, discusses sequencing therapies in prostate cancer.

PD-1 Pathway Combos Lead the Way in RCC Immunotherapy

March 16th 2015, 11:21am

The prospects for combining antiâ€“PD-1 pathway agents with other checkpoint blockade inhibitors or with agents that target angiogenesis are among the most promising immunotherapy approaches under development for patients with metastatic renal cell carcinoma.

Dr. Higano on Radium-223 for mCRPC

March 16th 2015, 10:04am

Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).

Making Sense of the Prostate Cancer Screening Debate

March 14th 2015, 1:51pm

Leonard G. Gomella, MD, told attendees at the 8th Annual IPCC that the decision to screen or not to screen for prostate cancer boiled down to "using common sense, shared decision making, and choosing the right patients to screen."

Proceed With Caution Is the Message on Active Surveillance

March 14th 2015, 12:06pm

Physicians should engage in careful patient selection before recommending active surveillance for prostate cancer, according to Mitchell C. Benson, MD.

Noted Astronaut Addresses Importance of Teamwork at Prostate Congress

March 14th 2015, 11:00am

In a similar fashion as astronauts, physicians can mitigate risks and improve outcomes with advanced planning and teamwork, four-time space shuttle commander Tom Henricks said during his keynote address at the Interdisciplinary Prostate Cancer Congress.

Dr. Richard Stock on Brachytherapy for Prostate Cancer

March 14th 2015, 10:29am